Melius Pharma

Melius Pharma is a private Swedish clinical stage pharmaceutical company developing treatments for severe diseases with high unmet needs at a reduced development risk.

Melius Pharma’s lead asset ME-015 (suplatast tosilate) is a first in class, oral treatment for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) in Phase 2 clinical development. ME-015 is a new chemical entity in all geographies outside Japan where it has been approved for three different indications since 1995 with an excellent safety and tolerability profile.

Melius Pharma’s largest shareholders are Linc AB and Fåhraeus Start-Up and Growth Fund.